Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The TESLA Trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke (TESLA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03805308
Recruitment Status : Recruiting
First Posted : January 15, 2019
Last Update Posted : February 21, 2021
Sponsor:
Information provided by (Responsible Party):
Dr. Osama O. Zaidat, Mercy Health Ohio

Brief Summary:
The primary objective of the trial is to establish the effectiveness of IAT (versus medical management) in patients with moderate-large infarcts (NCCT ASPECTS 2-5) at baseline, with adaptive enrichment to better define the upper limit of infarct volume for treatment eligibility. Furthermore, the investigators aim to determine whether certain subgroups of patients with large baseline infarcts will have a greater treatment benefit. Finally, the investigators will assess the agreement of ASPECTS scores between site investigators, the core imaging lab, and automated software.

Condition or disease Intervention/treatment Phase
Ischemic Stroke Procedure: Intra-arterial Therapy Not Applicable

Detailed Description:
Prospective, randomized, open-label, blinded endpoint study. Patients presenting with symptoms of AIS who have evidence of a moderate-large infarct volume (Non-contrast CT Alberta Stroke Program Early CT score [NCCT ASPECTS] 2-5 in the anterior circulation will be assigned to either best medical management alone (including IV rtPA) or intra-arterial treatment (IAT) with mechanical thrombectomy added to best medical management. Each treated patient will be followed and assessed for 3 months after randomization.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: TESLA is a pragmatic, phase III, prospective, randomized, open-label, blinded endpoint, multicenter trial. Patients with moderate-large infarcts will be assigned to either best medical management alone (including intravenous recombinant tissue-type plasminogen activator (IV rtPA)) or intra-arterial treatment (IAT) with mechanical thrombectomy added to best medical management. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the instructions for use (IFU). Patients will be enrolled at up to 25 centers over an anticipated three-year period, with an additional year for trial closeout.
Masking: Single (Outcomes Assessor)
Masking Description:

The patient and the treating physician will be aware of the treatment assignment. Assessment of outcome on NIHSS and mRS will be performed by a certified rater blinded to the treatment allocation. Each site must designate one or more individual(s) to perform these blinded assessments at 24 (16-36) hours, 6 ± 1 days or discharge (whichever is earlier), 30 days ± 7 days, and 90 days ± 30 days from randomization.

Neuroimaging core lab evaluation will also be assessed in a blinded manner, except for angiographic revascularization grading which will only be performed for the intra-arterial treatment arm.

Information on treatment allocation will be stored separately from the main study database. An unblinded independent statistician will combine treatment allocation data with the clinical data in order to report to the DSMB. A second blinded statistician will be part of the steering committee.

Primary Purpose: Treatment
Official Title: The TESLA Trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke
Actual Study Start Date : July 16, 2019
Estimated Primary Completion Date : July 16, 2022
Estimated Study Completion Date : November 1, 2022

Arm Intervention/treatment
No Intervention: Medical Management
Patients randomized to the medical therapy arm will receive standard medical therapy based on current AHA guidelines.
Experimental: Intra-arterial Therapy
For patients randomized to the intra-arterial therapy arm, sites will use local protocols for femoral access, sedation, heparin infusion, monitoring, etc. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the IFU.
Procedure: Intra-arterial Therapy
Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.
Other Name: Thrombectomy




Primary Outcome Measures :
  1. Utility-weighted 90-day Modified Rankin Score [ Time Frame: 90 days post randomization ]

    Scale used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Scale ranges from 0-6 where 0 represents no symptoms and 6 represents death.

    0 = No symptoms at all.

    1. = No significant disability despite symptoms; able to carry out all usual duties and activities.
    2. = Slight disability; unable to carry out all previous activities but able to look after own affairs without assistance.
    3. = Moderate disability requiring some help, but able to walk without assistance.
    4. = Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance.
    5. = Severe disability; bedridden, incontinent, and requiring constant nursing care and attention.
    6. = Death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18 to 85 years of age
  2. Presenting with symptoms consistent with an acute ischemic stroke
  3. Imaging evidence of an anterior circulation occlusion of the Internal Carotid Artery (ICA) terminus and/or Middle Cerebral Artery Main Stem (MCA M1) segment
  4. NIHSS score >6 at the time of randomization
  5. Ability to randomize within 24 hours of stroke onset
  6. Pre-stroke mRS score 0-1
  7. Ability to obtain signed informed consent

Imaging evidence of moderate-large infarct defined as:

1. NCCT ASPECTS 2-5

Exclusion Criteria:

  1. Females who are pregnant, or those of child-bearing potential with positive urine or serum beta Human Chorionic Gonadotropin (HCG) test
  2. Known severe allergy (more than a rash) to contrast media uncontrolled by medications
  3. Refractory hypertension (defined as persistent systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg)
  4. CT evidence of the following conditions:

    • Midline shift or herniation
    • Evidence of intracranial hemorrhage
    • Mass effect with effacement of the ventricles
  5. Computed Tomography Angiography (CTA) evidence suggestive of difficult endovascular access per the treating interventionalist
  6. Presence of cervical ICA occlusion (e.g., related to atherosclerotic disease or dissection)
  7. Rapidly improving neurological status prior to randomization to NIHSS <6
  8. Bilateral strokes or multiple intracranial occlusions
  9. Intracranial tumors
  10. Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant therapy with an International Normalized Ratio (INR) of >3.0 or Partial Thromboplastin Time (PTT) >3 times of normal
  11. Baseline platelet count <30,000 per microliter (µl)
  12. Life expectancy less than 90 days prior to stroke onset
  13. Participation in another randomized clinical trial that could confound the evaluation of the study
  14. Any other condition (in the opinion of the site investigator) that precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was performed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03805308


Contacts
Layout table for location contacts
Contact: Mary S Patterson, MS 419-251-2335 mspatterson@mercy.com

Locations
Show Show 35 study locations
Sponsors and Collaborators
Mercy Health Ohio
Investigators
Layout table for investigator information
Principal Investigator: Albert J Yoo, MD, PhD Texas Stroke Institute
Principal Investigator: Osama O Zaidat, MD, MS Mercy Health St. Vincent Medical Center
Layout table for additonal information
Responsible Party: Dr. Osama O. Zaidat, Neuroscience and Stroke Medical Director, Mercy Health Ohio
ClinicalTrials.gov Identifier: NCT03805308    
Other Study ID Numbers: 2018-49
First Posted: January 15, 2019    Key Record Dates
Last Update Posted: February 21, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: All shared data will be aggregate.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dr. Osama O. Zaidat, Mercy Health Ohio:
Stroke
Ischemic Stroke
Thrombectomy
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebral Infarction
Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia